IL-1 beta derivatives and drugs

Claim 1

A polypeptide characterized in that the polypeptide has a modified amino acid sequence fulfilling at least one of the following requirements a) to d) in the amino acid sequence of interleukin-lβ represented by the formula (A). a) At least one amino acid residue selected from among Ala at the l-position, Val at the 3-position, Arg at the 4-­position, Ser at the 5-position, Cys at the 8-position, Arg at the ll-position, His at the 30-position, Cys at the 7l-position, Lys at the 93-position, Lys at the 97-­position, Arg at the 98-position, Phe at the 99-position, Lys at the l03-position, Trp at the l20-position, Tyr at the l2l-position and Ser at the l53-position is deficient or replaced by another amino acid. b) The amino acid sequence of Ala at the l-position to Thr at the 9-position or at least one amino acid residue in this sequence is deficient (except that at least one amino acid residue selected from the group consisting of Ala at the l-position, Val at the 3-position, Arg at the 4-­position, Ser at the 5-position and Cys at the 8-position is deficient as stated in the requirement a)). c) The amino acid sequence of Lys at the l03 position to Ser at the l53-position or at least one amino acid residue in this sequence is deficient (except that at least one amino acid residue selected from the group consisting of Lys at the l03-position, Trp at the l20-position, Tyr at the l2l-position and Ser at the l53-position is deficient as stated in the requirement a)). d) Met, or the amino acid sequence of Met at the lʹ-­position to Asp at the ll6ʹ-position represeted by the following formula (B), or a portion of the sequence of the formula (B) toward its C terminal is attached to the N terminal of the formula (A)